There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aslan Pharmaceuticals (ASLN – Research Report), Urogen Pharma (URGN – Research Report) and Legend Biotech (LEGN – Research Report) with bullish sentiments.
Aslan Pharmaceuticals (ASLN)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Aslan Pharmaceuticals today and set a price target of $9.00. The company’s shares closed last Friday at $0.65, close to its 52-week low of $0.39.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
Aslan Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $9.50, implying a 1420.0% upside from current levels. In a report issued on March 13, Piper Sandler also reiterated a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Urogen Pharma (URGN)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma today and set a price target of $54.00. The company’s shares closed last Friday at $14.46.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
Currently, the analyst consensus on Urogen Pharma is a Strong Buy with an average price target of $44.00, which is a 203.7% upside from current levels. In a report issued on March 14, TD Cowen also maintained a Buy rating on the stock.
Legend Biotech (LEGN)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech, with a price target of $87.00. The company’s shares closed last Friday at $64.02.
According to TipRanks.com, Kapoor ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $86.83, representing a 31.7% upside. In a report issued on March 12, Raymond James also initiated coverage with a Buy rating on the stock with a $86.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ASLN:
- Biotech Alert: Searches spiking for these stocks today
- Aslan Pharmaceuticals price target lowered to $10 from $15 at Piper Sandler
- ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
- Aslan Pharmaceuticals announces $5M registered direct offering
- Piper ‘confident’ partner or buyer will see benefit of Aslan’s eblasakimab
